Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
Articles Authored by Andrew P. Han
Commercial service providers offer researchers a way to access spatial genomics technologies without the attendant risks of bringing them in-house.
The study from Zurich-based researchers, published in Genome Biology, highlighted the utility of different tools for different datasets.
10x Genomics Lowers Onboarding Costs for Labs to Get Into Single-Cell Projects With New Platform
Premium
The new Chromium Xo, launched earlier this month, only runs the firm's latest 3' gene expression assay and has a list price of $25,000.
US PTAB Invalidates 10x Genomics Single-Cell Patent
An inter partes review, filed by competitor Parse Biosciences, nullified one of three patents 10x alleged infringement of in a 2022 lawsuit against Parse.
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
Premium
Memorial Sloan Kettering Cancer Center is among the first healthcare systems to implement the rapid sequencing assay, which can consolidate single-gene tests.
The UCLA spinout offers a way to capture and assay antibodies and other proteins secreted by individual cells without specialized instrumentation.
German Bioinformatics Startup Goenomics Offers Biology-First Approach to Novel Genome Annotations
Premium
The University of Göttingen spinout is poised to help analyze many more genomes, thanks to a recent partnership with Dovetail Genomics.
Next-Gen Sequencing Helps Tie Differences in Sequence Changes to Physics of DNA, Protein Binding
Premium
Two methods published simultaneously in Science use the Illumina MiSeq instrument to help increase the throughput of single-molecule biophysics studies.
The approach enables better cellular lineage tracing and makes it easier to read out a cell's molecular history than with earlier CRISPR-based methods.
10x Genomics Lowers 2024 Revenue Guidance as Q2 Revenues Rise 4 Percent
The firm lowered guidance despite beating Wall Street expectations on both the top and bottom lines.